| Style | Citing Format |
|---|---|
| MLA | Manafi N, Ghiasvand F. "Reply to the Letter to the Editor “Azithromycin, Treatment in Covid-19”." International Journal of Antimicrobial Agents, vol. 57, no. 3, 2021, pp. -. |
| APA | Manafi N, Ghiasvand F (2021). Reply to the Letter to the Editor “Azithromycin, Treatment in Covid-19”. International Journal of Antimicrobial Agents, 57(3), -. |
| Chicago | Manafi N, Ghiasvand F. "Reply to the Letter to the Editor “Azithromycin, Treatment in Covid-19”." International Journal of Antimicrobial Agents 57, no. 3 (2021): -. |
| Harvard | Manafi N, Ghiasvand F (2021) 'Reply to the Letter to the Editor “Azithromycin, Treatment in Covid-19”', International Journal of Antimicrobial Agents, 57(3), pp. -. |
| Vancouver | Manafi N, Ghiasvand F. Reply to the Letter to the Editor “Azithromycin, Treatment in Covid-19”. International Journal of Antimicrobial Agents. 2021;57(3):-. |
| BibTex | @article{ author = {Manafi N and Ghiasvand F}, title = {Reply to the Letter to the Editor “Azithromycin, Treatment in Covid-19”}, journal = {International Journal of Antimicrobial Agents}, volume = {57}, number = {3}, pages = {-}, year = {2021} } |
| RIS | TY - JOUR AU - Manafi N AU - Ghiasvand F TI - Reply to the Letter to the Editor “Azithromycin, Treatment in Covid-19” JO - International Journal of Antimicrobial Agents VL - 57 IS - 3 SP - EP - PY - 2021 ER - |